Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice.
Bone cells isolated from the Hyp mouse, the murine homologue for hypophosphatemic vitamin D-resistant rickets, produce abnormal bone when transplanted to either normal or phosphate-supplemented Hyp mice. To assess whether correction of the bone formation by mutant cells transplanted into either normal or Hyp mice could be achieved in the presence of supraphysiologic serum concentrations of 1.25-dihydroxyvitamin D3 (1.25-(OH)2D3), recipient mice of both genotypes were infused continuously with 1.25-(OH)2D3 (0.2 micrograms/kg/day). Bone nodules present in transplants recovered after 14 days were characterized by measuring the osteoid thickness and volume. Administration of 1.25-(OH)2D3 to Hyp mice corrected the defective bone formation by normal cells but not by pair-transplanted Hyp cells, despite normalization of serum phosphate levels and 3-fold increases in serum 1.25-(OH)2D3. The osteoid thickness and volume in Hyp transplants into 1.25-(OH)2D3-treated Hyp mice were, however, markedly reduced down to values observed for Hyp transplants into recipient normal mice. Administration of 1.25-(OH)2D3 to normal mice improved further bone formation by mutant cells without affecting that by pair-transplanted normal cells. Administration of 24.25-(OH)2D3 (1 microgram/kg/day) combined with 1.25-(OH)2D3 to recipient mice of both genotypes prevented the sharp fall in serum 24.25-(OH)2D3 but was not more beneficial than 1.25-(OH)2D3 alone for improving bone formation by transplanted Hyp cells. These observations demonstrate an abnormal response of the mutant cells to the extracellular environment and support the concept of an intrinsic osteoblast defect in the Hyp mouse.
Ecarot
B
B
Shriners Hospital, Department of Surgery, Montreal, Quebec, Canada.
Glorieux
F H
FH
Desbarats
M
M
Travers
R
R
Labelle
L
L
D015650:24,25-Dihydroxyvitamin D 3 / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D000469:Alkaline Phosphatase / Q000097:blood; D000704:Analysis of Variance; D000818:Animals; D001846:Bone Development / Q000187:drug effects*; D002117:Calcitriol / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D017690:Cell Transplantation; D004359:Drug Therapy, Combination; D005260:Female; D007015:Hypophosphatemia, Familial / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D010710:Phosphates / Q000097:blood; D012886:Skull / Q000166:cytology; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects
D010710:Phosphates; D015650:24,25-Dihydroxyvitamin D 3; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002118:Calcium